The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Estimated Market Size Of The Parathyroid Disease Treatment Market During 2026–2030?
The parathyroid disease treatment market has experienced robust expansion in recent years. Projections indicate it will expand from $2.37 billion in 2025 to $2.54 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.2%. Historically, this growth was primarily driven by factors such as the increasing prevalence of hyperparathyroidism, limited understanding of parathyroid conditions, reliance on conventional hormone replacement methods, a scarcity of sophisticated surgical options, and constraints within hospital pharmacy infrastructure.
The parathyroid disease treatment market is projected to experience substantial expansion over the next few years. It is forecast to reach $3.31 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.8%. This growth during the forecast period can be attributed to the increasing demand for calcimimetics and bisphosphonates, advancements in parathyroid imaging and diagnostics, the development of homecare and telemedicine solutions, regulatory support for precision medicine, and the expanding network of specialty centers for endocrine disorders. Key trends anticipated in the forecast period include the increasing adoption of calcimimetics and bisphosphonates, a rising preference for parenteral over oral administration in severe cases, the expansion of hospital and specialty care settings, a growing focus on personalized hormone replacement therapies, and the integration of lifestyle and nutritional interventions into treatment plans.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25866&type=smp
What Drivers Are Expected To Influence The Parathyroid Disease Treatment Market During The Forecast Period?
The growing incidence of chronic kidney disease (CKD) is anticipated to drive the expansion of the parathyroid disease treatment market in the foreseeable future. Chronic kidney disease is a long-term ailment where the kidneys gradually lose their functional capacity, leading to imbalances in essential minerals such as calcium and phosphorus. The increasing occurrence of chronic kidney disease (CKD) is primarily attributed to the rising cases of diabetes, as persistently elevated blood sugar levels can damage the kidneys’ filtering units over time, resulting in diabetic nephropathy. Treatment for parathyroid disease plays a vital role in managing chronic kidney disease (CKD) by addressing secondary hyperparathyroidism, a frequent complication in advanced CKD that disrupts the balance of calcium and phosphorus, contributes to bone disease, and promotes vascular calcification. For instance, in May 2024, data from the Centers for Disease Control and Prevention (CDC), a US-based government public health agency, showed that over one in seven adults in the US, which translates to approximately 35.5 million people or roughly 14%, were estimated to have chronic kidney disease in 2023, with nearly 90% of those affected being unaware of their condition. Therefore, the increasing prevalence of chronic kidney disease is a key factor propelling the growth of the parathyroid disease treatment market.
How Are The Various Segments Of The Parathyroid Disease Treatment Market Categorized?
The parathyroid disease treatment market covered in this report is segmented –
1) By Treatment: Calcimimetics, Bisphosphonates, Plicamycin, Hormone Replacement Therapy, Other Treatments
2) By Route Of Administration: Oral, Parenteral
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users
Subsegments:
1) By Calcimimetics: Cinacalcet, Etelcalcetide
2) By Bisphosphonates: Alendronate, Ibandronate, Risedronate, Zoledronic Acid
3) By Plicamycin: Mithramycin (Plicamycin) Monotherapy, Combination Therapies Involving Plicamycin
4) By Hormone Replacement Therapy: Estrogen Therapy, Progesterone Therapy, Combined Hormonal Therapies, Selective Estrogen Receptor Modulators (SERMs)
5) By Other Treatments: Parathyroid Hormone (PTH) Analogues, Surgery (Parathyroidectomy), Dietary Supplements, Lifestyle And Nutritional Interventions
What Trends Are Affecting The Expansion Of The Parathyroid Disease Treatment Market?
Leading companies in the parathyroid disease treatment market are prioritizing the creation of advanced products, such as parathyroid hormone prodrugs, to enhance calcium regulation and minimize dosing frequency for patients with hypoparathyroidism. Parathyroid hormone (PTH) prodrugs are inactive compounds that transform into active PTH within the body, thereby regulating calcium and phosphate balance. For instance, in August 2024, Ascendis Pharma A/S, a Denmark-based biopharmaceutical company, obtained US Food and Drug Administration (FDA) approval for YORVIPATH (palopegteriparatide), which is a prodrug of parathyroid hormone (PTH[1-34]) intended for the treatment of chronic hypoparathyroidism in adults. This once-daily therapy ensures continuous parathyroid hormone exposure over 24 hours, providing an alternative to traditional calcium and vitamin D supplementation by directly addressing the root hormone deficiency. The successful approval of YORVIPATH emphasizes the increasing focus on sophisticated hormone replacement therapies aimed at improving treatment adherence and achieving superior clinical outcomes for individuals suffering from parathyroid disorders.
Which Major Firms Influence Developments In The Parathyroid Disease Treatment Market?
Major companies operating in the parathyroid disease treatment market are AstraZeneca PLC, Amgen Inc., Kyowa Kirin Co. Ltd., OPKO Health Inc., Septerna Inc., Entera Bio Ltd., Visen Pharmaceuticals (Shanghai) Co. Ltd., Ascendis Pharma A/S, Aeterna Zentaris Inc., MBX Biosciences Inc., Crinetics Pharmaceuticals Inc., Vidasym Inc., Rani Therapeutics LLC, Pathalys Pharma Inc.
Read the full parathyroid disease treatment market report here:
https://www.thebusinessresearchcompany.com/report/parathyroid-disease-treatment-global-market-report
Which Region Is Forecast To Lead The Parathyroid Disease Treatment Market In Terms Of Market Size?
Asia-Pacific was the largest region in the parathyroid disease treatment market in 2025. The regions covered in the parathyroid disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Parathyroid Disease Treatment Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=25866&type=smp
Browse Through More Reports Similar to the Global Parathyroid Disease Treatment Market 2026, By The Business Research Company
Transthyretin Amyloidosis Treatment Market Report 2026
Anti Thyroid Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/anti-thyroid-drugs-global-market-report
Thyroid Cancer Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/thyroid-cancer-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model